Call us now : +91 80 28528900, 01, 02


DeQuantoTM Adalimumab (Humira ) PK ELISA KIT (Catalog # PK1002)

CATALOG # : PK1002

Pack Size : 1 x 96 wells

QTY : 1

PRICE : Enquire

  • Product Specifications

    The PK (PharmacoKinetics) ELISA Kit is specifically designed to detect the amount/ concentration of the drug Adalimumab in human serum/plasma

    • strong>Sensitivity : 5.2 ng/ml
    • Very cost effective.
    • Assay Duration : 3 -3.5 hrs
    • Assay Range : 5.2 – 200 ng/ml
    • Assay Matrix : Tested and Validated for Human serum or plasma
    • Specificity : Specifically to anti-TNF drug
    • Interference : No interference observed for Rituximab (Mabthera) in Assay range
    • Note: "Humira®" is a registered trademark of AbbVie Inc.

    The kit is based on very robust ELISA technique and with very high sensitivity.

  • Product Summary


    Adalimumab (Humira) is a therapeutic fusion protein specific for Tumor Necrosis Factor-Alpha (TNF-?) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Humira® is a registered trademark of Abbott Laboratories. Adalimumab specifically binds to TNF alpha and blocks its interaction with cell surface TNF receptors and reduces the inflammation and subsequently improves the patients health.

    Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.

    EMA Bio-analytical Method Validation Guidelines and industry-recommended practices for ligand-binding assays were used for validation of this kit. This Adalimumab ELISA kit has been developed for specific quantification of Adalimumab concentration in human serum or plasma with high sensitivity and reproducibility.

    Assay Principle

    The DeQuantoTM Adalimumab (Humira) PK ELISA kit is an ELISA based immunoassay. The Adalimumab present in the sample binds to pre coated TNF-? on polystyrene microtiter plate. Non bound or the excess substances are removed by washing. Horseradish Peroxidase (HRP) labeled antibody is added to the wells which binds to the TNF/ Adalimumab complex in the wells. Following a wash to remove any unbound antibody-enzyme reagent, substrate solution is added to the wells. A color product is formed in proportion to the amount of Adalimumab present in the sample or standards. The color development is stopped by addition of a stop solution. The absorbance is measured at 450 nm in a microtiter plate reader. The concentration of Adalimumab in a sample can be interpolated from the standard curve.